1. Home
  2. CLW vs IFRX Comparison

CLW vs IFRX Comparison

Compare CLW & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearwater Paper Corporation

CLW

Clearwater Paper Corporation

N/A

Current Price

$19.45

Market Cap

338.7M

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$1.73

Market Cap

303.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLW
IFRX
Founded
1926
2007
Country
United States
Germany
Employees
3710
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
338.7M
303.4M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
CLW
IFRX
Price
$19.45
$1.73
Analyst Decision
Hold
Strong Buy
Analyst Count
4
9
Target Price
★ $21.50
$7.77
AVG Volume (30 Days)
102.2K
★ 444.7K
Earning Date
10-27-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $1,555,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.06
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 12.42
N/A
52 Week Low
$11.73
$0.80
52 Week High
$23.59
$2.95

Technical Indicators

Market Signals
Indicator
CLW
IFRX
Relative Strength Index (RSI) 41.62 40.02
Support Level $19.25 $1.58
Resistance Level $20.80 $2.38
Average True Range (ATR) 0.83 0.12
MACD -0.22 -0.03
Stochastic Oscillator 15.17 14.00

Price Performance

Historical Comparison
CLW
IFRX

About CLW Clearwater Paper Corporation

Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: